Recent Activity

Loading...

KRYS

Krystal Biotech, Inc. · NASDAQ

Performance

+3.38%

1W

-3.52%

1M

+44.49%

3M

+66.87%

6M

+32.27%

YTD

+86.08%

1Y

Profile

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Investment Analysis Report: KRYS

Overview

In this investment analysis report, we will delve into a comprehensive evaluation of KRYS, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash fl...

See more ...

Technical Analysis of KRYS 2024-05-10

Overview:

In analyzing the technical indicators for KRYS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisio...

See more ...

Recent News & Updates